%0 Journal Article
%T SGLT-2 Inhibitors: The Magic Bullet for Cardio-Renal Protection in Type 2 DM
%A Rushi Patel
%A Terry Oroszi
%J Pharmacology & Pharmacy
%P 490-507
%@ 2157-9431
%D 2024
%I Scientific Research Publishing
%R 10.4236/pp.2024.1512027
%X Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a promising class of medications for type 2 diabetes mellitus (DM2) treatment. This study aims to evaluate the clinical efficacy, safety, and potential benefits of SGLT-2 inhibitors in improving cardiovascular and renal outcomes in DM2 patients. A comprehensive review of clinical trials and studies on SGLT-2 inhibitors was conducted. SGLT-2 inhibitors significantly improve glycemic control, reduce cardiovascular mortality, and lower the risk of renal events in DM2 patients. SGLT-2 inhibitors offer substantial cardio-renal protection in DM2 management, though further research is needed to optimize their use.
%K SGLT-2 Inhibitors
%K Type 2 Diabetes Mellitus
%K Cardiovascular Outcomes
%K Renal Protection
%K Glycemic Control
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=138592